Glax­o­SmithK­line, As­traZeneca butt heads over li­cens­ing rights to key PARP in­hibitor — re­port

Ahead of Glax­o­SmithK­line’s planned split in­to two com­pa­nies and spin-off of its con­sumer di­vi­sions, the phar­ma’s ma­jor British ri­val is re­port­ed­ly su­ing over a drug that could prove piv­otal to CEO Em­ma Walm­s­ley’s plans.

As­traZeneca has filed a court claim in the UK ar­gu­ing for a larg­er share of sales from the GSK can­cer drug Ze­ju­la, the Times of Lon­don re­port­ed Sun­day. Ze­ju­la, the cen­ter­piece of GSK’s $5 bil­lion ac­qui­si­tion of Tesaro from late 2018, was de­vel­oped in part by tech­nol­o­gy owned by As­traZeneca and is li­censed to GSK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER